Promising prostate cancer drug gets extended trial for those already benefiting

NCT ID NCT04145375

ENROLLING_BY_INVITATION Disease control Sponsor: Zenith Epigenetics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694, often combined with enzalutamide (Xtandi), if they are already seeing benefits from it in a previous study. About 40 participants will be enrolled to monitor side effects and long-term outcomes like tumor response and survival. The goal is to keep providing a potentially helpful treatment while gathering more safety data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZEN003694 (a drug) and enzalutamide (Xtandi)
What this could lead to: If successful, this could offer a way for men with advanced prostate cancer to keep receiving a promising treatment that is helping them.
What could go wrong: This is an early-phase continuation study with only 40 participants, so results may not apply broadly. Side effects are possible, and the drug is still investigational.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCRPC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MCRPC

Contacts and locations

Locations

Oregon Health & Science University

Portland, Oregon, 97239, United States
University of California San Francisco Medical Center

San Francisco, California, 94104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.